204 related articles for article (PubMed ID: 20004576)
21. A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1.
Cai L; Gochin M
Antimicrob Agents Chemother; 2007 Jul; 51(7):2388-95. PubMed ID: 17452484
[TBL] [Abstract][Full Text] [Related]
22. Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.
Ding X; Zhang X; Chong H; Zhu Y; Wei H; Wu X; He J; Wang X; He Y
J Virol; 2017 Sep; 91(18):. PubMed ID: 28659478
[TBL] [Abstract][Full Text] [Related]
23. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket.
Eckert DM; Malashkevich VN; Hong LH; Carr PA; Kim PS
Cell; 1999 Oct; 99(1):103-15. PubMed ID: 10520998
[TBL] [Abstract][Full Text] [Related]
24. Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1.
Chong H; Yao X; Qiu Z; Sun J; Zhang M; Waltersperger S; Wang M; Liu SL; Cui S; He Y
FASEB J; 2013 Mar; 27(3):1203-13. PubMed ID: 23233535
[TBL] [Abstract][Full Text] [Related]
25. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity.
Jiang S; Debnath AK
Biochem Biophys Res Commun; 2000 Apr; 270(1):153-7. PubMed ID: 10733920
[TBL] [Abstract][Full Text] [Related]
26. Multimerized CHR-derived peptides as HIV-1 fusion inhibitors.
Nomura W; Hashimoto C; Suzuki T; Ohashi N; Fujino M; Murakami T; Yamamoto N; Tamamura H
Bioorg Med Chem; 2013 Aug; 21(15):4452-8. PubMed ID: 23800723
[TBL] [Abstract][Full Text] [Related]
27. Progress in targeting HIV-1 entry.
Ryser HJ; Flückiger R
Drug Discov Today; 2005 Aug; 10(16):1085-94. PubMed ID: 16182193
[TBL] [Abstract][Full Text] [Related]
28. Functional and structural characterization of HIV-1 gp41 ectodomain regions in phospholipid membranes suggests that the fusion-active conformation is extended.
Korazim O; Sackett K; Shai Y
J Mol Biol; 2006 Dec; 364(5):1103-17. PubMed ID: 17045292
[TBL] [Abstract][Full Text] [Related]
29. Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket.
Zhang X; Zhu Y; Hu H; Zhang S; Wang P; Chong H; He J; Wang X; He Y
Front Cell Infect Microbiol; 2018; 8():51. PubMed ID: 29535974
[TBL] [Abstract][Full Text] [Related]
30. Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket.
Bai Y; Xue H; Wang K; Cai L; Qiu J; Bi S; Lai L; Cheng M; Liu S; Liu K
Amino Acids; 2013 Feb; 44(2):701-13. PubMed ID: 22961335
[TBL] [Abstract][Full Text] [Related]
31. Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41.
Lu L; Yu F; Cai L; Debnath AK; Jiang S
Curr Top Med Chem; 2016; 16(10):1074-90. PubMed ID: 26324044
[TBL] [Abstract][Full Text] [Related]
32. Addition of artificial salt bridge by Ile646Lys mutation in gp41 coiled-coil domain regulates 6-helical bundle formation.
Zhao L; Hu ZW; Tong P; Chen YX; Zhao YF; Li YM
Bioorg Med Chem Lett; 2013 May; 23(9):2727-32. PubMed ID: 23522564
[TBL] [Abstract][Full Text] [Related]
33. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.
Münch J; Ständker L; Adermann K; Schulz A; Schindler M; Chinnadurai R; Pöhlmann S; Chaipan C; Biet T; Peters T; Meyer B; Wilhelm D; Lu H; Jing W; Jiang S; Forssmann WG; Kirchhoff F
Cell; 2007 Apr; 129(2):263-75. PubMed ID: 17448989
[TBL] [Abstract][Full Text] [Related]
34. Dimeric C34 Derivatives Linked through Disulfide Bridges as New HIV-1 Fusion Inhibitors.
Kobayakawa T; Ebihara K; Honda Y; Fujino M; Nomura W; Yamamoto N; Murakami T; Tamamura H
Chembiochem; 2019 Aug; 20(16):2101-2108. PubMed ID: 31012222
[TBL] [Abstract][Full Text] [Related]
35. Fusion intermediates of HIV-1 gp41 as targets for antibody production: design, synthesis, and HR1-HR2 complex purification and characterization of generated antibodies.
Mzoughi O; Gaston F; Granados GC; Lakhdar-Ghazal F; Giralt E; Bahraoui E
ChemMedChem; 2010 Nov; 5(11):1907-18. PubMed ID: 20922745
[TBL] [Abstract][Full Text] [Related]
36. Structure-based design of substituted biphenyl ethylene ethers as ligands binding in the hydrophobic pocket of gp41 and blocking the helical bundle formation.
Liu B; Joseph RW; Dorsey BD; Schiksnis RA; Northrop K; Bukhtiyarova M; Springman EB
Bioorg Med Chem Lett; 2009 Oct; 19(19):5693-7. PubMed ID: 19699090
[TBL] [Abstract][Full Text] [Related]
37. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
Gustchina E; Hummer G; Bewley CA; Clore GM
J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842
[TBL] [Abstract][Full Text] [Related]
38. Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug.
Teixeira C; Gomes JR; Gomes P; Maurel F; Barbault F
Eur J Med Chem; 2011 Apr; 46(4):979-92. PubMed ID: 21345545
[TBL] [Abstract][Full Text] [Related]
39. An effective conjugation strategy for designing short peptide-based HIV-1 fusion inhibitors.
Liang G; Wang H; Chong H; Cheng S; Jiang X; He Y; Wang C; Liu K
Org Biomol Chem; 2016 Aug; 14(33):7875-82. PubMed ID: 27454320
[TBL] [Abstract][Full Text] [Related]
40. Glycosylated enfuvirtide: a long-lasting glycopeptide with potent anti-HIV activity.
Cheng S; Chang X; Wang Y; Gao GF; Shao Y; Ma L; Li X
J Med Chem; 2015 Feb; 58(3):1372-9. PubMed ID: 25594223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]